Navigation Links
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Date:6/26/2008

tements

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended March 31, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda'
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons ... the key link between the medical device industry and ... more in the coming years as the device industry ... According to research by benchmarking firm, Best Practices, ... gain an important edge is by harnessing new technology ...
(Date:12/22/2014)... , Dec. 22, 2014   TRU-D SmartUVC ... no-touch UV disinfection robot, announced today that the General ... contract through November 2019.   This newly ... engage all levels of government purchasers, including Department of ... well as Homeland Security contacts purchasing solutions for the ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Inc.(Nasdaq: MSHL ), an oncology company focused on ... today that it will host its Annual Meeting of Stockholders ... offices of Morgan, Lewis & Bockius LLP, located at 101 ... vote on certain matters, including the approval of the transactions ...
... 10, 2011 Eli Lilly and Company (NYSE: ... Ph.D., will lead Lilly,s oncology research efforts as the vice ... research. In this innovative new role created by ... of both Lilly and its subsidiary, ImClone. Plowman will be ...
Cached Medicine Technology:Marshall Edwards to Host Annual Meeting of Stockholders 2Marshall Edwards to Host Annual Meeting of Stockholders 3Lilly Announces New Vice President of Oncology Research 2Lilly Announces New Vice President of Oncology Research 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... When head lice hits a home or school, parents ... rid of it while keeping it from taking over the ... the solution right in their neighborhood: Lice Troopers . ... full spectrum head lice screening and treatment services to families ... Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
(Date:12/25/2014)... December 25, 2014 Plugin creators from ... 5k. A fully customizable business presentation tool made specifically ... the ProFire 5k business tool, users can now display ... CEO of Pixel Film Studios. “ProFire 5k gives users ... to add professionalism to a presentation” , Pixel Film ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... . , Montreal, January 14, 2009 Canadian researchers ... cancer. According to a recent study from the Universit de ... Journal of Biological Chemistry , the protein ARF1 plays a ... tumours. Targeting this protein with drug therapy may provide hope ...
... Only Non-Drowsy Allergy Medicine in a Liquid-Filled Capsule ... 14 Schering-Plough Corporation (NYSE: SGP ... Liqui-Gels(R), the first and only non-drowsy allergy medicine ... CLARITIN(R) Liqui-Gels(R) provide powerful liquid relief for the ...
... affected by chronic inflammation without knowing much about it. FlameEz.com is ... inflammation, the root cause of many of the most feared illnesses ... ... PA (PRWEB) January 14, 2009 -- Millions of Americans are affected ...
... N.C., Jan. 14 Germs are everywhere,and especially dangerous ... can age hands, ignite near flame and make kids ... www.remi-d.com ) dispenses with these maladies with subtle,scents, convenience ... sanitizers have been sick with laziness. Remi-D is ...
... Va., Jan. 14 ... solutions for healthcare, announced that the Unbound(TM) Platform ... iPod(R) touch devices. Adding delivery of iPhone applications ... Palm OS devices strengthens Unbound Medicine,s position as ...
... Specialty Line for Tweens and TeensCARLSBAD, Calif., Jan. 14 ... ages clarifying products that are 100% natural and ultra-effective ... The products include the Everyday Clarifying Lotion, Everyday Clarifying ... be debuting at the New York International Gift Fair, ...
Cached Medicine News:Health News:New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available 2Health News:New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available 3Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 2Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 3Health News:No Germs, No Fires, No Mess: New Product Makes Good Health Easy and Natural 2Health News:Unbound Medicine Announces Download Support for iPhone(TM) and iPod(R) Touch Devices 2Health News:Glory for Girls Announces All-Natural Clarifying Products for Clear and Radiant Skin 2
... of flexible lighting products. The first is ... different sizes 5", 10", and 15" (refers ... light). These lights are for use in ... ,The second group of flexible lights is ...
... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...
... Aaron manufactures two groups of flexible lighting ... and non-sterile in three different sizes 5", ... shaft portion of the light). These lights ... light is needed., ,The second group ...
Designed to be used for neuromuscular blockage monitoring. Provides for easy placement over the ulnar nerve on a patient's wrist. Dual element permits non-invasive monitoring using a single electrode...
Medicine Products: